Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.30
-0.05 (-0.35%)
At close: Nov 20, 2024, 4:00 PM
14.13
-0.17 (-1.19%)
Pre-market: Nov 21, 2024, 4:00 AM EST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 80.16B INR in the quarter ending September 30, 2024, with 16.51% growth. This brings the company's revenue in the last twelve months to 299.87B, up 12.37% year-over-year. In the fiscal year ending March 31, 2024, Dr. Reddy's Laboratories had annual revenue of 279.16B with 13.54% growth.
Revenue (ttm)
299.87B INR
Revenue Growth
+12.37%
P/S Ratio
n/a
Revenue / Employee
11,086,476 INR
Employees
27,048
Market Cap
11.98B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fresenius Medical Care AG | 21.46B |
| Universal Health Services | 15.42B |
| Solventum | 8.22B |
| Smith & Nephew | 5.64B |
| AptarGroup | 3.57B |
| Genmab | 2.97B |
| BioMarin Pharmaceutical | 2.75B |
| Globus Medical | 2.48B |
RDY News
- 15 days ago - Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Dr. Reddy's Q2 & H1FY25 Financial Results - Business Wire
- 26 days ago - Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year - Business Wire
- 5 weeks ago - Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month - Business Wire
- 6 weeks ago - Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma - Business Wire
- 7 weeks ago - Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries - Business Wire
- 3 months ago - Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug - Business Wire
- 3 months ago - Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy - Seeking Alpha